$IRMD

Susi Roger E. sold $70K of IRMD (indirect holdings)

Susi Roger E. (CEO, President, Chairman) sold 775 indirectly-held shares of IRADIMED CORP (IRMD) at $89.79 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Susi Roger E.
Published Jun 2, 2026, 6:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRMD
Neutral
medium confidence
Mentioned
$IRMD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRMDNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider behavior but does not include new operational, financial, or regulatory information.

02

Market read

Traders may monitor for follow-on insider buys/sells, but this specific event is unlikely to drive a durable repricing absent other catalysts.

03

What to watch

The filing is indirect ownership and the share count is relatively small versus typical float; without additional insider activity context, signal-to-noise is low.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-02) for a sale executed 2026-06-01

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for IRMD.

Company-level read

Ticker impact

$IRMDNeutralMedium confidence
Context

IRMD CEO/President/Chairman Susi Roger sold 775 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-02.

Expected impact

Likely limited immediate price impact; any reaction is more sentiment/flow-driven than fundamental.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan, reducing the likelihood the sale reflects new negative information.

Market effects

Minimal; this is company-specific insider transaction disclosure with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may be routine liquidity management rather than a bearish signal.

Key entities

  • IRADIMED CORP

    Subject of the SEC Form 4 insider sale disclosed in the article.

  • Susi Roger E.

    CEO, President, Chairman, and 10% owner who sold shares under a pre-arranged 10b5-1 plan.

Related articles

$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.